FHTX - Foghorn Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
FHTX price evolution
FHTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $140.66 | $80.96 | $82.04 | |
| Short term investments | $146.23 | $127.41 | $153.72 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $271.23 | $289.62 | $211.52 | $240.18 |
| Long term investments | ||||
| Property, plant & equipment | $34.58 | $36.26 | $40.72 | $42.91 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $38.96 | $43.48 | $45.73 | |
| Total investments | $146.23 | $127.41 | $153.72 | |
| Total assets | $308.37 | $328.58 | $255 | $285.92 |
| Current liabilities | ||||
| Accounts payable | $3.45 | $4.81 | $5.63 | $6.26 |
| Deferred revenue | $290.73 | $297.62 | $302.67 | |
| Short long term debt | $8.38 | $8.67 | $8.52 | |
| Total current liabilities | $56.82 | $50.87 | $52.06 | $58.44 |
| Long term debt | $32.54 | $34.31 | $36.55 | |
| Total noncurrent liabilities | $292.04 | $300.43 | $304.67 | |
| Total debt | $40.92 | $42.98 | $45.07 | |
| Total liabilities | $336.66 | $342.91 | $352.49 | $363.11 |
| Shareholders' equity | ||||
| Retained earnings | -$538.68 | -$519.56 | -$496.58 | -$471.56 |
| Other shareholder equity | $0.36 | -$0.34 | -$0.5 | -$0.83 |
| Total shareholder equity | -$14.32 | -$97.49 | -$77.19 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $82.04 | $53.92 | $102.87 | $94.53 |
| Short term investments | $153.72 | $293.58 | $53.15 | $92.97 |
| Net receivables | $300 | |||
| Inventory | ||||
| Total current assets | $240.18 | $351.4 | $459.56 | $190.69 |
| Long term investments | ||||
| Property, plant & equipment | $42.91 | $49.4 | $56.08 | $62.33 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $45.73 | $53.48 | $60.21 | $64.91 |
| Total investments | $153.72 | $293.58 | $53.15 | $92.97 |
| Total assets | $285.92 | $404.88 | $519.77 | $255.59 |
| Current liabilities | ||||
| Accounts payable | $6.26 | $5.41 | $3.82 | $3.68 |
| Deferred revenue | $302.67 | $336.82 | $351.05 | $14.57 |
| Short long term debt | $8.52 | $5.97 | $6.99 | $3.98 |
| Total current liabilities | $58.44 | $55.2 | $48.69 | $18.85 |
| Long term debt | $36.55 | $45.54 | $51.34 | $78.02 |
| Total noncurrent liabilities | $304.67 | $349.57 | $374.21 | $90.56 |
| Total debt | $45.07 | $51.51 | $58.33 | $82 |
| Total liabilities | $363.11 | $404.77 | $422.9 | $109.41 |
| Shareholders' equity | ||||
| Retained earnings | -$471.56 | -$373.14 | -$264.26 | -$162.94 |
| Other shareholder equity | -$0.83 | -$3.99 | -$0.01 | -$0.01 |
| Total shareholder equity | -$77.19 | $0.11 | $96.87 | $146.19 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.81 | $6.89 | $5.05 | $5.77 |
| Cost of revenue | ||||
| Gross Profit | $6.89 | $5.05 | $5.77 | |
| Operating activities | ||||
| Research & development | $23.8 | $25.53 | $24.2 | |
| Selling, general & administrative | $7.33 | $7.71 | $7.02 | |
| Total operating expenses | $31.66 | $33.52 | $33.24 | $31.23 |
| Operating income | -$26.63 | -$28.19 | -$25.46 | |
| Income from continuing operations | ||||
| EBIT | -$22.98 | -$25.02 | -$22.12 | |
| Income tax expense | $1.99 | |||
| Interest expense | $3.5 | |||
| Net income | ||||
| Net income | -$19.12 | -$22.98 | -$25.02 | -$24.11 |
| Income (for common shares) | -$22.98 | -$25.02 | -$24.11 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $34.16 | $19.23 | $1.32 | $0.43 |
| Cost of revenue | ||||
| Gross Profit | $34.16 | $19.23 | $1.32 | $0.43 |
| Operating activities | ||||
| Research & development | $109.69 | $105.62 | $80.33 | $57.72 |
| Selling, general & administrative | $32.37 | $30.75 | $21.73 | $11.25 |
| Total operating expenses | $142.06 | $136.37 | $102.05 | $68.96 |
| Operating income | -$107.91 | -$117.14 | -$100.73 | -$68.53 |
| Income from continuing operations | ||||
| EBIT | -$94.2 | -$108.88 | -$99.41 | -$67.82 |
| Income tax expense | $4.23 | |||
| Interest expense | $1.91 | $0.98 | ||
| Net income | ||||
| Net income | -$98.43 | -$108.88 | -$101.32 | -$68.8 |
| Income (for common shares) | -$98.43 | -$108.88 | -$101.32 | -$68.8 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$22.98 | -$25.02 | -$24.11 | |
| Operating activities | ||||
| Depreciation | $2.24 | $2.25 | $2.25 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.17 | $3.22 | $3.05 | |
| Total cash flows from operations | -$25.54 | -$29.34 | -$27.54 | |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.1 | -$0.04 | |
| Investments | -$17.96 | $27.2 | $37.42 | |
| Total cash flows from investing | -$52.2 | -$17.98 | $27.09 | $37.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $103.21 | $1.17 | $0.19 | |
| Net borrowings | ||||
| Total cash flows from financing | $105.42 | $103.21 | $1.17 | $0.19 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.66 | $59.69 | -$1.08 | $10.03 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$98.43 | -$108.88 | -$101.32 | -$68.8 |
| Operating activities | ||||
| Depreciation | $8.66 | $7.9 | $7.51 | $5.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16.19 | $14.34 | $8.38 | $2.96 |
| Total cash flows from operations | -$118.11 | $193.61 | -$50.25 | -$31.29 |
| Investing activities | ||||
| Capital expenditures | -$1.22 | -$1.21 | -$3.31 | -$15.93 |
| Investments | $145.67 | -$243.11 | $39.49 | -$92.98 |
| Total cash flows from investing | $144.45 | -$244.32 | $36.17 | -$108.91 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.78 | $1.76 | $43.62 | $123.34 |
| Net borrowings | -$21.2 | $4.27 | ||
| Total cash flows from financing | $1.78 | $1.76 | $22.42 | $217.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $28.12 | -$48.95 | $8.34 | $77.27 |
News
Fundamentals
| Market cap | $232.94M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 55.59M |
| Revenue | $25.52M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$91.22M |
| Revenue Q/Q | -55.33% |
| Revenue Y/Y | -21.66% |
| P/E ratio | -2.55 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 9.13 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.64 |
|---|---|
| ROA | -30.98% |
| ROE | N/A |
| Debt/Equity | -4.70 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.77 |
| Quick ratio | N/A |